Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview in-person at 10:45 a.m. EST on February 14, 2022 at the BIO CEO & Investor Conference, which is being held at the New York Marriott Marquis in New York City, NY on February 14-17.
圣迭戈，2022年2月7日(环球通讯社)--专注于开发基于免疫学的预防和治疗疾病疗法的临床期生命科学公司启示录生物科学公司(纳斯达克代码：REVIB)(以下简称“公司”或“启示录”)今天宣布，其首席执行官詹姆斯·罗克将于美国东部时间上午10点45分亲自介绍公司概况。2022年2月14日，在BIO首席执行官和投资者大会上，该会议将于2月14日至17日在纽约州纽约市的纽约万豪酒店(New York Marriott Marquis)举行。
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
罗尔克先生将在整个会议期间面对面和虚拟地参加一对一会议。
About Revelation Biosciences Inc.
关于启示录生物科学公司
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation's therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
启迪生物科学公司是一家临床阶段的生命科学公司，专注于开发基于免疫学的预防和治疗疾病的疗法。启示录有几款候选产品正在开发中。REVTx-99是主要的候选治疗药物，是一种鼻腔免疫调节剂，用于预防或治疗由各种呼吸道病毒引起的感染，如SARS-CoV-2，包括其变种、甲型和乙型流感、副流感、鼻病毒和呼吸道合胞病毒。REVTx-99还被开发用于其他适应症，如：过敏性鼻炎和慢性鼻塞。REVTx-200是一种鼻腔免疫调节剂辅助剂，可与肌肉注射疫苗结合使用，以获得更完全的免疫力。REVTx-200基于与REVTx-99相同的技术。除了启示号的治疗流水线外，启示号还在开发REVDx-501，这是一种快速的家庭使用诊断方法，可以用来检测任何呼吸道病毒感染，无论病毒类型或毒株，而不需要专门的仪器。
For more information on Revelation, please visit .
有关启示录的更多信息，请访问。
Company Contacts
公司联系人
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
桑德拉·韦德里克(Sandra Vedrick)
投资者关系和人力资源部副总裁
启示录生物科学公司。
电子邮件：svedrick@revbiosciences.com
and
和
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
切斯特·齐格蒙特(Chester Zygmont)，III
首席财务官
启示录生物科学公司。
电子邮件：czygmont@revbiosciences.com